(Updates with further details in 2nd and 16th paragraphs, share price in last paragraph)
By Jenny Ruth
May 22 (BusinessDesk) - AFT Pharmaceuticals posted a narrower annual loss as interest and other finance costs swamped
operating earnings and says it’s negotiating the refinancing of its debt at more favourable interest rates.
Interest payments jumped more than 54 percent as borrowing increased and other increases in finance costs reflected
foreign exchange movements.
The marketer of over-the-counter medicines including Maxigesic pain killers says it made a net loss of $2.4 million for
the year ended March, down from a $12.7 million net loss the previous year.
Operating earnings turned to a $6.1 million profit from a $10.1 million loss the previous year. Sales rose 5 percent to
$85.1 million and spending on research and development fell 69 percent to $2.6 million.
The company says excluding its since-sold lower margin hospital products - at the end of the 2018 financial year for New
Zealand and early in the 2019 year for Australia - sales were up 14 percent.
Operating cash flow turned positive to the tune of $1.1 million from an outflow of $9.2 million the previous year and
AFT had $6.9 million in cash at March 31.
“The completion of the key Maxigesic clinical trials, the return to generating positive operating profits and cash flow
and the continued strong growth in our broad portfolio of OTC medicines represent significant achievements,” says chair
David Flacks in a statement.
“We are now at a pivotal point in our development. We are well positioned to continue to build on the strong position we
enjoy, particularly in OTC medicines in New Zealand and Australia,” Flacks says.
“We have made good progress in Southeast Asia and we have continued to deliver on the significant out-licensing
potential we see for Maxigesic in large international markets.”
Founder and managing director Hartley Atkinson says he expects AFT to deliver strongly improved operating earnings for
the current year.
The company had a $41.8 million loan at March 31, up from $30.7 million a year earlier, from specialist healthcare
investor CRG and was paying 13.5 percent interest. That loan matures at the end of the 2020 financial year.
“Although CRG has offered to extend the loan, we have begun negotiations with local banks to refinance our facilities at
more attractive rates. Reflecting the positive outlook for the business, we are confident we will achieve that goal,”
In the meantime, AFT has established a $15 million interim banking facility with Bank of New Zealand which it says "uses
the existing security arrangements between AFT, BNZ and CRG."
The company intends to repay US$9.5 million of the CRG facility in the next few days and plans to repay the balance on
March 31 next year.
"We are grateful for the support and financial flexibility CRG has provided to AFT over five years of significant
research and development investment and, as this business matures, it is appropriate for the company to seek alternative
AFT should be able to reduce its interest costs to current commercial lending rates of about 8 percent.
Atkinson says he sees “significant potential” for AFT’s products in global markets.
“The timing is always difficult to forecast with certainty, not least because it is important that we find the right
partners to take our products through to commercialisation,” he says.
“At the same time, we continue to develop and commercialise line extensions of the Maxigesic range and other products
such as NasoSurf and Pascomer. Once achieved, all have the potential to generate significant shareholder value and
improve healthcare outcomes for patients around the globe.”
The company has made significant progress “but there remains significant work to be done to reach our true potential and
fully reward our shareholders,” Atkinson says.
AFT is targeting positive cash flow and an operating profit between $9-12 million and will update the market at its
annual meeting in August.
AFT shares fell 0.4 percent to $2.69 in early trading, below its 2015 float price of $2.80, but 7.6 percent higher than
a year ago.